Local biotech invests in erectile dysfunction drug

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

The company – which specializes in repurposing drugs already approved for other purposes – has signed a letter of intent to license a sublingual formation for drugs used to treat erectile dysfunction. Sublingual formations (which allow drugs to be dissolved under the tongue) absorb more quickly and therefore take effect sooner.

"We expect to move this product through pivotal trials and through regulatory approval over the next year and intend to begin marketing within two years," said Pacific Therapeutics CEO Douglas Unwin.

"We expect to complete the license in the first quarter of 2013, and move rapidly to the late-stage clinical trials and marketing."

In 2006, the market for drugs for treating erectile dysfunction exceeded $3 billion, the company said.

Pacific Therapeutics has two other drugs in the pipeline, both of which are for the treatment of scarring of human tissue.

Its lead product, PTL-202, is a combination of drugs being tested for efficacy in treating idiopathic pulmonary fibrosis, a progressive scarring of the lungs. The drug is already approved by the Food and Drug Administration in the U.S. and is currently in stage one of clinical trials.

nbennett@biv.com

@nbennett_biv

comments powered by Disqus

Also Read

More From Innovation

Ottawa is cutting a cheque worth $31.4 million for B.C. business accelerators and incubators looking to ...

Read Article

By the end of this year, Victoria-based studios will launch seven new video games — a sign the high-value sector is growing rapidly  

Read Article

Vancouver’s BroadbandTV is seeing rapid growth, including an increase in monthly impressions of...

Read Article

More than half of female MBA-holders working in technology firms leave the industry because of male-dominated business culture, a new report reveals

Read Article

San Francisco-based company now valued at more than $1 billion, while its Vancouver-based CEO aims to ramp up hiring at Yaletown office  

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×